Torsade de Pointes Due to QT Prolongation after Pulmonary Vein Isolation for Persistent Atrial Fibrillation

Akio Chikata¹², Takeshi Kato³, Kazuo Usuda¹, Shuhei Fujita³, Kan-Ichi Otowa¹, Michiro Maruyama¹, Kenshi Hayashi² and Masayuki Takamura²

Abstract:
We herein report a 60-year-old woman with long-standing persistent atrial fibrillation (AF) who developed QT prolongation and torsade de pointes (TdP) after pulmonary vein isolation (PVI). When electrical cardioversion was performed three months before PVI, prominent QT prolongation was not observed. QT prolongation emerged after PVI and was sustained until AF recurrence on the third day after ablation, and TdP disappeared along with AF recurrence. PVI affects the ganglionated plexi around the atrium, leading to modification of the intrinsic cardiac autonomic system. This case indicates that PVI has the potential risk of inducing lethal ventricular arrhythmias due to QT prolongation.

Key words: torsade de pointes, QT prolongation, pulmonary vein isolation

(Intern Med 60: 2089-2092, 2021)  
(DOI: 10.2169/internalmedicine.6627-20)

Introduction
Catheter ablation is a highly effective therapeutic strategy for atrial fibrillation (AF) (1, 2). Pulmonary vein isolation (PVI) is a cornerstone of AF ablation. The ablation line of PVI transects the sites where the major atrial ganglionated plexi (GP) exists. GP ablation carries a risk of increasing atrial and ventricular vulnerability to arrhythmias, and GP ablation induced QT prolongation after myocardial infarction in a canine model (3, 4, 5). QT prolongation and lethal ventricular arrhythmias related to PVI and antiarrhythmic drugs have also been reported (6).
We herein report a patient who developed QT prolongation and torsade de points (TdP) after PVI for persistent AF without an antiarrhythmic drug.

Case Report
A 60-year-old woman with long-standing persistent AF was referred to our hospital for catheter ablation. She had no structural heart disease or inherited arrhythmias. Her prescribed medication included bisoprolol fumarate 1.25 mg daily; edoxaban tosilate hydrate 30 mg daily; olmesartan medoxomil 20 mg daily; sodium valproate 200 mg twice daily; and ifenprodil tartrate 20 mg three times a day. Bisoprolol fumarate was discontinued two days before the ablation procedure. We performed electrical cardioversion three months before the ablation procedure, and prominent QT prolongation was not observed early after cardioversion. Intravenous injection of 150 mg thiopental sodium was performed before electrical cardioversion (Fig. 1A).
Recurrence of AF occurred, and a 12-lead electrocardiogram (ECG) showed no QT prolongation before ablation (Fig. 1B). Wide antral ipsilateral PVI using radiofrequency (RF) ablation was performed under the guidance of three-dimensional (3D) ultrasound geometries and 3D merged computed tomography (CT) using the CARTO 3 system (Biosense Webster, Diamond Bar, USA). RF ablation was performed under deep sedation with noninvasive positive pressure ventilation support. Deep sedation was initiated with 6 μg/kg/h dexmedetomidine for 10 min and fentanyl citrate 0.1 mg. Subsequently, it was maintained with 0.6 μg/kg/h dexmedetomidine. The total dexmedetomidine dose was 150 μg. First-pass isolation was achieved in both PVs, and electrical cardioversion was performed to restore sinus
We performed right PVI first to avoid the vagal reflex, followed by left PVI (Fig. 2). Intravenous injection of 50 mg thiopental sodium was performed before electrical cardioversion. The bidirectional block was confirmed, and a dissociated potential was observed in both PVs. No complications were observed during the procedure, and the patient returned to the general ward in sinus rhythm. The total procedure time was 104 minutes.

Seventeen hours after the procedure, TdP suddenly occurred and spontaneously terminated. A 12-lead ECG revealed prominent QT prolongation. Laboratory data showed a slightly low serum magnesium (Mg) level of 1.6 mg/dL. Creatine phosphokinase levels were within the normal limits (85 IU/L). T wave inversions were found in I, aVL, and V2, but there were no obvious local wall motion abnormalities on bedside echocardiography. QT prolongation persisted, and TdP was not suppressed despite normalization of the serum Mg level using intravenous administration of Mg sulfate (Fig. 3). TdP appeared occasionally but resolved spontaneously and did not progress to ventricular fibrillation. TdP disappeared together with AF recurrence three days after ablation. QT prolongation and negative T waves were also improved (Fig. 4).

A genetic test using the TruSight Cardio sequencing panel (Illumina, San Diego, USA) detected no known gene mutations related to long QT syndrome. On the sixth day after the procedure, coronary angiography showed no obstruction or stenosis, and left ventriculography revealed no local wall motion abnormalities. She did not take any antiarrhythmic drugs before or after ablation.

**Discussion**

The QT interval is affected by various factors, including the heart rate, electrolyte disorders, autonomic nervous system, and anesthesia. In this case, the QT interval was prolonged after PVI, and the prolongation was sustained despite...
the normalization of electrolyte disorders. Exaggerated QT prolongation after cardioversion has been reported (7); however, in the present case, QT prolongation was not observed when electrical cardioversion was performed three months before the ablation. Her prescribed medications did not change after the ablation procedures. These observations suggest the involvement of the PVI procedure in QT prolongation.

The ablation line of PVI for AF transects the sites where the major atrial GP exists; therefore, PVI inadvertently modifies the intrinsic cardiac autonomic nervous system, which is a determinant of the QT interval (8). In animal models, GP ablation is associated with a prolonged QT interval and increased atrial/ventricular vulnerability to arrhythmias (3, 4). QT prolongation has also been observed after PVI, especially in the acute phase, in humans (9). Although TdP associated with QT prolongation after PVI with antiarrhythmic drugs has been reported (6), no antiarrhythmic drugs were used in the present case. Approximately 30% of acquired long QT syndrome cases have a known clinical long QT syndrome gene mutation (10), but no relevant genetic background was detected in this case; nevertheless, discontinuation of the beta-blocker two days before the procedure may have been involved in QT prolongation after the ablation procedure.

This case indicates the potential risk of lethal arrhythmia induced by QT prolongation due to PVI, even in patients without a known genetic background of long QT syndrome or antiarrhythmic drug prescription.

The authors state that they have no Conflict of Interest (COI).

---

**Figure 2.** Three-dimensional computed tomography merged voltage map after pulmonary vein isolation. Each tag shows an ablation point.

**Figure 3.** QT prolongation was observed two days after pulmonary vein isolation. The HR was 71 bpm. The raw QT was 540 ms, and the Fridericia-corrected QTc was 549 ms. T wave inversions were found in I, aVL, and V2. Torsade de pointes (TdP) occurred despite the normalization of serum Mg levels. TdP disappeared with the recurrence of atrial fibrillation.
A 12-lead electrocardiogram was acquired on the third day after the procedure, showing atrial fibrillation. The raw QT was 362 ms, and the Fridericia-corrected QTc was 440 ms. QT prolongation and negative T waves were improved.

References
1. Packer DL, Mark DB, Robb RA, et al.; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321: 1261-1274, 2019.
2. Marrouche NF, Brachmann J, Andresen D, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378: 417-427, 2018.
3. He B, Lu Z, He W, et al. Effects of ganglionated plexi ablation on ventricular electrophysiological properties in normal hearts and after acute myocardial ischemia. Int J Cardiol 168: 86-93, 2013.
4. Mao J, Yin X, Zhang Y, et al. Ablation of epicardial ganglionated plexi increases atrial vulnerability to arrhythmias in dogs. Circ Arhythm Electrophysiol 7: 711-7, 2014.
5. Wu B, Xu S, Dai R, Hong M, Wu H, Lin R. Epicardial ganglionated plexi ablation increases the inducibility of ventricular tachyarrhythmias in a canine postmyocardial infarction model. J Cardiovasc Electrophysiol 30: 741-746, 2019.
6. Park YM, Cha MS, Kang WC, et al. Torsades de pointes associated with QT prolongation after catheter ablation of paroxysmal atrial fibrillation. Indian Pacing Electrophysiol J 17: 146-149, 2017.
7. Choy AM, Darbar D, Dell’Orto S, et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 34: 396-401, 1999.
8. Diedrich A, Jordan J, Shannon JR, et al. Modulation of QT interval during autonomic nervous system blockade in humans. Circulation 106: 2238-2243, 2002.
9. Chikata A, Kato T, Usuda K, et al. Prolongation of QT interval after pulmonary vein isolation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 31: 2371-2379, 2020.
10. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 37: 1456-1464, 2016.